Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top 10 Correlated Stocks
HUM
In the News
BlackRock's DeSpirito: Brace For Stubborn Inflation
Inflation is easing, says a top thinker for BlackRock, the world's largest asset manager. But it's not falling to what Americans have grown used to.
Humana Proves Vertically Integrated Healthcare Works
Health insurance and wellness provider Humana (NYSE: HUM) stock has been outperforming the benchmark indexes trading up 4.6% for the year
Top Health Care Stock Holds Up During Market Downturn, Builds Base
UnitedHealth is building a base as this managed health care stock outperforms the market. The post Top Health Care Stock Holds Up During Market Downturn, Builds Base appeared first on Investor's Business Daily.
4 HMO Stocks to Watch Despite Escalating Technology Expenses
A growing customer base and numerous contract wins might drive the Medical-HMO industry. However, high expenses related to technology advancements and a shortage of nurses will dampen margins.
Is There More Upside For Humana Stock?
Humana's revenue rising a significant 66% to $89.4 billion over the last twelve months, compared to $53.8 billion in 2017, 2.
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.
Humana, CVS reportedly eyeing Cano Health acquisition
Yahoo Finance Live anchors Brad Smith and Julie Hyman discuss reports that Humana and CVS are interested in acquiring Cano Health.
CANO Stock Moves as Humana, CVS Consider Acquisition
Source: metamorworks / Shutterstock Cano Health (NYSE: CANO ) stock is moving on Friday from reports that Humana (NYSE: HUM ) and CVS (NYSE: CVS ) are considering buying the company. According to insider sources, both companies have expressed interest in buying out CANO and bringing the company into their folds.
Cano Health Courts CVS, Humana as Buyout Suitors
Humana could be considering buying Cano Health, according to a Wall Street Journal (WSJ) report citing unnamed sources. This comes amid a broader movement of healthcare giants buying out primary-care providers.
Cano Health CEO: Humana is a great partner
Dr. Marlow Hernandez, Cano Health CEO, joins CNBC's Contessa Brewer to discuss the health care space. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Bonawyn Eison, Dan Nathan and Brian Kelly.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 372.11 | 413.95 | 484.04 | 583.63 | 645.47 | |
| Net income per share | 16.94 | 12.24 | 20.19 | 25.47 | 22.79 | |
| Operating cash flow per share | 28.04 | 15.81 | 39.42 | 42.66 | 17.58 | |
| Free cash flow per share | 24.4 | 11.35 | 33.93 | 35.36 | 7.35 | |
| Cash per share | 94.12 | 89.97 | 112.09 | 130.31 | 128.89 | |
| Book value per share | 68.11 | 73.91 | 89.79 | 103.84 | 124.95 | |
| Tangible book value per share | 43.84 | 43.78 | 59.17 | 67.72 | 18.43 | |
| Share holders equity per share | 68.11 | 73.91 | 89.79 | 103.84 | 124.95 | |
| Interest debt per share | 36.7 | 46.97 | 45.75 | 54.94 | 102.15 | |
| Market cap | 40.79B | 42.12B | 46.01B | 50.65B | 49.7B | |
| Enterprise value | 41.81B | 46.02B | 47.85B | 52.95B | 59.12B | |
| P/E ratio | 16.66 | 25.03 | 17 | 15.04 | 16.94 | |
| Price to sales ratio | 0.76 | 0.74 | 0.71 | 0.66 | 0.6 | |
| POCF ratio | 10.07 | 19.39 | 8.71 | 8.98 | 21.97 | |
| PFCF ratio | 11.57 | 26.99 | 10.12 | 10.83 | 52.53 | |
| P/B Ratio | 4.14 | 4.15 | 3.82 | 3.69 | 3.09 | |
| PTB ratio | 4.14 | 4.15 | 3.82 | 3.69 | 3.09 | |
| EV to sales | 0.78 | 0.81 | 0.74 | 0.69 | 0.71 | |
| Enterprise value over EBITDA | 8.81 | 16.28 | 11.16 | 9.5 | 13.27 | |
| EV to operating cash flow | 10.32 | 21.18 | 9.06 | 9.39 | 26.14 | |
| EV to free cash flow | 11.86 | 29.48 | 10.52 | 11.33 | 62.5 | |
| Earnings yield | 0.06 | 0.04 | 0.06 | 0.07 | 0.06 | |
| Free cash flow yield | 0.09 | 0.04 | 0.1 | 0.09 | 0.02 | |
| Debt to equity | 0.48 | 0.43 | 0.41 | 0.44 | 0.66 | |
| Debt to assets | 0.64 | 0.6 | 0.59 | 0.61 | 0.64 | |
| Net debt to EBITDA | 0.21 | 1.38 | 0.43 | 0.41 | 2.11 | |
| Current ratio | 1.38 | 1.56 | 1.65 | 0.99 | 0.89 | |
| Interest coverage | 0 | 0 | 0 | 0 | 9.66 | |
| Income quality | 1.65 | 1.29 | 1.95 | 1.67 | 0.77 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.09 | 0.16 | 0.11 | 0.1 | 0.12 | |
| Sales general and administrative to revenue | 0.12 | 0.13 | 0.11 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.13 | 0.16 | 0.14 | 0.14 | 0.31 | |
| Capex to operating cash flow | -0.13 | -0.28 | -0.14 | -0.17 | -0.58 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Capex to depreciation | -1.08 | -1.15 | -1.28 | -1.56 | -1.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 161.14 | 142.67 | 201.98 | 243.94 | 253.14 | |
| ROIC | 0 | 0 | 0 | 0 | 0.11 | |
| Return on tangible assets | 0.1 | 0.08 | 0.11 | 0.11 | 0.1 | |
| Graham Net | -21.43 | -15.43 | -9.09 | -23.91 | -80.1 | |
| Working capital | 4.84B | 6.07B | 7.82B | -190M | -1.64B | |
| Tangible asset value | 6.34B | 6.02B | 7.93B | 8.95B | 2.37B | |
| Net current asset value | 66M | 1.7B | 2.85B | -8.36B | -14.81B | |
| Invested capital | 0.51 | 0.61 | 0.49 | 0.51 | 0.8 | |
| Average receivables | 996M | 1.08B | 1.1B | 1.14B | 1.48B | |
| Average payables | 11.91B | 10.15B | 11.06B | 12.16B | 12.48B | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 5.8 | 6.51 | 5.94 | 5.38 | 7.97 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 62.96 | 56.07 | 61.45 | 67.8 | 45.79 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.25 | 0.17 | 0.22 | 0.25 | 0.18 | |
| Capex per share | -3.64 | -4.45 | -5.49 | -7.29 | -10.23 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 160.42 | 161.04 | 163.7 | 188.83 | 187.02 | |
| Net income per share | 4.57 | 11.91 | -0.11 | 7.33 | 5.5 | |
| Operating cash flow per share | 2.8 | 22.06 | -0.75 | 2.38 | 7.58 | |
| Free cash flow per share | 0.24 | 19.52 | -3.63 | 0.06 | 5.37 | |
| Cash per share | 130.92 | 140.24 | 128.96 | 141.45 | 143.77 | |
| Book value per share | 115.34 | 126.52 | 125.03 | 120.68 | 122.43 | |
| Tangible book value per share | 74.5 | 21.93 | 18.44 | 12.23 | 31.43 | |
| Share holders equity per share | 115.34 | 126.52 | 125.03 | 120.68 | 122.43 | |
| Interest debt per share | 58.18 | 97.96 | 100.39 | 105.42 | 105.3 | |
| Market cap | 56.97B | 50.01B | 59.66B | 55.24B | 59.22B | |
| Enterprise value | 61B | 58.21B | 69.08B | 63.67B | 67.29B | |
| P/E ratio | 24.22 | 8.17 | -1.07K | 14.85 | 21.27 | |
| Price to sales ratio | 2.76 | 2.42 | 2.83 | 2.3 | 2.5 | |
| POCF ratio | 158.26 | 17.64 | -621.44 | 182.91 | 61.75 | |
| PFCF ratio | 1.84K | 19.93 | -127.75 | 7.89K | 87.09 | |
| P/B Ratio | 3.84 | 3.08 | 3.71 | 3.61 | 3.82 | |
| PTB ratio | 3.84 | 3.08 | 3.71 | 3.61 | 3.82 | |
| EV to sales | 2.95 | 2.81 | 3.28 | 2.66 | 2.84 | |
| Enterprise value over EBITDA | 59.81 | 30.32 | 314.02 | 42.14 | 46.96 | |
| EV to operating cash flow | 169.46 | 20.53 | -719.62 | 210.82 | 70.17 | |
| EV to free cash flow | 1.97K | 23.2 | -147.93 | 9.1K | 98.96 | |
| Earnings yield | 0.01 | 0.03 | 0 | 0.02 | 0.01 | |
| Free cash flow yield | 0 | 0.05 | -0.01 | 0 | 0.01 | |
| Debt to equity | 0.41 | 0.71 | 0.66 | 0.74 | 0.73 | |
| Debt to assets | 0.61 | 0.64 | 0.64 | 0.67 | 0.67 | |
| Net debt to EBITDA | 3.95 | 4.27 | 42.85 | 5.58 | 5.63 | |
| Current ratio | 0.97 | 0.95 | 0.89 | 0 | 1.57 | |
| Interest coverage | 0 | 0 | 34.59 | 0 | 12.03 | |
| Income quality | 0.61 | 1.85 | 6.86 | 0.32 | 1.38 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.15 | 0.06 | -6.5 | 0.1 | 0.14 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.14 | 0.3 | 0.31 | 0.3 | 0.25 | |
| Capex to operating cash flow | -0.91 | -0.11 | 3.86 | -0.98 | -0.29 | |
| Capex to revenue | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | |
| Capex to depreciation | -1.94 | -1.8 | -1.91 | -1.44 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 108.89 | 184.15 | 17.5 | 141.04 | 123.1 | |
| ROIC | 0 | 0 | 0.11 | 0 | 0.04 | |
| Return on tangible assets | 0.02 | 0.05 | 0 | 0.03 | 0.02 | |
| Graham Net | -35.35 | -74.74 | -80.15 | -83.74 | -83.73 | |
| Working capital | -497M | -749M | -1.64B | 0 | 9.85B | |
| Tangible asset value | 9.59B | 2.82B | 2.37B | 1.55B | 3.98B | |
| Net current asset value | -9B | -15.04B | -14.81B | 0 | -4.09B | |
| Invested capital | 0.5 | 0.77 | 0.8 | 0.87 | 0.85 | |
| Average receivables | 2.81B | 2.53B | 2.49B | 3.17B | 3.27B | |
| Average payables | 14.31B | 14.48B | 14.02B | 15.24B | 15.34B | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 10.63 | 8.17 | 7.75 | 11.92 | 12.81 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 8.47 | 11.01 | 11.61 | 7.55 | 7.02 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.04 | 0.09 | 0 | 0.06 | 0.04 | |
| Capex per share | -2.56 | -2.54 | -2.88 | -2.32 | -2.21 |
Frequently Asked Questions
What is Humana Inc. stock symbol ?
Humana Inc. is a US stock , located in Louisville of Kentucky and trading under the symbol HUM
Is Humana Inc. buy or a sell ?
27 stock analysts have 27 predictions with a medium analyst target price of $514.85. The lowest prediction is $450 and the highest is $570
What is HUM stock prediction ?
With a median analyst target price of $540.78, 9 stock analysts have made 9 forecasts in last 90 days. $494 is the lowest and $570 is the greatest projection.
What is Humana Inc. stock quote today ?
Humana Inc. stock price is $485.19 today.
Is Humana Inc. stock public?
Yes, Humana Inc. is a publicly traded company.
Company Profile
- Volume Average 842.53K
- Market Capitalization 61.4B
- Employee 95.5K
- CEO Mr. Bruce Broussard
- Headquarters Louisville,KENTUCKY,US
- IPO Date 1971-05-18
-
Website
https://www.humana.com 
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
